| Patient | Franklin D. Roosevelt |
|---|---|
| Date of birth | 1964-01-30 |
| Identifiers | MRN HR-ET002-SYN; SSN (made up) 000-02-5130 |
| Document date | 2026-11-01 |
| Author | Nathaniel Brooks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for breathlessness, orthopnea, and leg swelling. Concerns: Breathlessness, poor sleep from orthopnea, and leg swelling are cutting short his workdays; Wants to stop smoking without losing his edge at work. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2026-03-27 to 2026-04-10 | completed | S |
| Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2026-04-10 | active | S |
| Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-03-27 to 2026-04-10 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-04-10 to 2026-06-26 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-06-26 | active | S |
| Spironolactone 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-10 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 | active | S |
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 to 2026-06-26 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 | active | S |
| Nicotine 21 mg/24 hr transdermal patch, apply one patch daily | Apply one patch to the skin daily | Topical route | 2026-03-27 to 2026-06-26 | completed | S |
| Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart | 750 mg intravenously, two doses one week apart | Intravenous route | 2026-04-10 to 2026-04-17 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Transthoracic echocardiography | 2026-04-10 to 2026-04-10 | completed | S |
| Transthoracic echocardiography | 2026-09-25 to 2026-09-25 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | Influenza vaccine, 2025-2026 season | completed | S |
| 2026-04-10 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2021-05-03 | Tdap vaccine | completed | S |
| 2026-10-23 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-23 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| August 25, 1921 | Paralytic illness in August 1921, diagnosed at the time as infantile paralysis (polio); paraplegic thereafter, with leg braces from early 1922 | D (CLM-0003) |
| Proposed in 2003 about the 1921 illness | Guillain-Barré syndrome proposed retrospectively as the cause of the 1921 paralysis; disputed | R (CLM-0004) |
| May 1941 | Severe iron deficiency anemia in May 1941, hemoglobin reported at 4.5 g/100 mL | D (CLM-0005) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died in 1900; cause not recorded in the cited source | D (CLM-0009) | |
| mother | Died in September 1941; cause not recorded in the cited source | D (CLM-0009) |
| Concern | Status | Evidence |
|---|---|---|
| Breathlessness, poor sleep from orthopnea, and leg swelling are cutting short his workdays | active | S |
| Wants to stop smoking without losing his edge at work | active | S |
Most recent measures: Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 410 on 2026-09-25; Sodium [Moles/volume] in Serum or Plasma 135 on 2026-07-27; Potassium [Moles/volume] in Serum or Plasma 4.9 on 2026-07-27; Creatinine [Mass/volume] in Serum or Plasma 1.42 on 2026-07-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 56 on 2026-07-27; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-07-27; Hemoglobin [Mass/volume] in Blood 13.6 on 2026-06-26; Ferritin [Mass/volume] in Serum or Plasma 236 on 2026-06-26; Iron saturation [Mass Fraction] in Serum or Plasma 27 on 2026-06-26; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-03-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-09-25; Hemoglobin A1c/Hemoglobin.total in Blood 5.9 on 2026-03-27; Albumin/Creatinine [Mass Ratio] in Urine 22 on 2026-09-25; Overall summary score [KCCQ-12] 78 on 2026-09-25; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-23; Left ventricular Ejection fraction 45 on 2026-09-25; Total score [AUDIT-C] 2 on 2026-10-23 [S]
Strengths and supports: Supports: spouse, an adult daughter who encouraged this visit, and close staff [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findings | active | confirmed | I11.0 | S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D. |
| Heart failure with reduced ejection fraction, NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode. |
| Nicotine dependence, cigarettes | active | confirmed | F17.210 | S — Synthetic modern diagnosis linked to documented cigarette smoking. |
| Iron deficiency anemia in heart failure, repleted with intravenous iron | resolved | confirmed | D50.9 | S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S. |
| Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed | active | provisional | B91 | S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R. |
| Prediabetes | active | confirmed | R73.03 | S — Synthetic finding from the baseline HbA1c. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| Acute viral gastroenteritis with mild volume depletion, resolved with oral rehydration and a short hold of heart failure medicines | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-27 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 2850 | pg/mL | <=125 pg/mL | High | S |
| 2026-03-27 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-27 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 70 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-27 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-03-27 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-03-27 | Ferritin [Mass/volume] in Serum or Plasma | 48 | ng/mL | 30-400 ng/mL | Normal | S |
| 2026-03-27 | Iron saturation [Mass Fraction] in Serum or Plasma | 16 | % | 20-50% | Low | S |
| 2026-03-27 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | <=99 mg/dL | High | S |
| 2026-03-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | <=5.6% | High | S |
| 2026-03-27 | Albumin/Creatinine [Mass Ratio] in Urine | 64 | mg/g | <=30 mg/g | High | S |
| 2026-03-27 | Overall summary score [KCCQ-12] | 38 | {score} | S | ||
| 2026-03-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-04-10 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-10 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.29 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 63 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-10 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-10 | Left ventricular Ejection fraction | 30 | % | 50-70% | Low | S |
| 2026-06-26 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 980 | pg/mL | <=125 pg/mL | High | S |
| 2026-06-26 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-26 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.24 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-06-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-26 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-26 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-06-26 | Ferritin [Mass/volume] in Serum or Plasma | 236 | ng/mL | 30-400 ng/mL | Normal | S |
| 2026-06-26 | Iron saturation [Mass Fraction] in Serum or Plasma | 27 | % | 20-50% | Normal | S |
| 2026-06-26 | Overall summary score [KCCQ-12] | 64 | {score} | S | ||
| 2026-06-26 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-25 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 410 | pg/mL | <=125 pg/mL | High | S |
| 2026-09-25 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-25 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-25 | Creatinine [Mass/volume] in Serum or Plasma | 1.21 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-25 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 68 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-25 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-25 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-09-25 | Albumin/Creatinine [Mass Ratio] in Urine | 22 | mg/g | <=30 mg/g | Normal | S |
| 2026-09-25 | Left ventricular Ejection fraction | 45 | % | 50-70% | Low | S |
| 2026-09-25 | Overall summary score [KCCQ-12] | 78 | {score} | S | ||
| 2026-07-27 | Sodium [Moles/volume] in Serum or Plasma | 135 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.42 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 56 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-07-27 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-23 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-23 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-27 | Body height | 188 | cm | S |
| 2026-03-27 | Body weight | 88 | kg | S |
| 2026-03-27 | Body mass index (BMI) [Ratio] | 24.9 | kg/m2 | S |
| 2026-03-27 | Systolic blood pressure | 186 | mm[Hg] | S |
| 2026-03-27 | Diastolic blood pressure | 108 | mm[Hg] | S |
| 2026-03-27 | Heart rate | 96 | /min | S |
| 2026-03-27 | Respiratory rate | 22 | /min | S |
| 2026-03-27 | Body temperature | 36.9 | Cel | S |
| 2026-03-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 93 | % | S |
| 2026-04-10 | Body height | 188 | cm | S |
| 2026-04-10 | Body weight | 85 | kg | S |
| 2026-04-10 | Body mass index (BMI) [Ratio] | 24 | kg/m2 | S |
| 2026-04-10 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-04-10 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-04-10 | Heart rate | 84 | /min | S |
| 2026-04-10 | Respiratory rate | 18 | /min | S |
| 2026-04-10 | Body temperature | 36.8 | Cel | S |
| 2026-04-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-06-26 | Body height | 188 | cm | S |
| 2026-06-26 | Body weight | 83 | kg | S |
| 2026-06-26 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 2026-06-26 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-26 | Heart rate | 70 | /min | S |
| 2026-06-26 | Respiratory rate | 16 | /min | S |
| 2026-06-26 | Body temperature | 36.7 | Cel | S |
| 2026-06-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-25 | Body height | 188 | cm | S |
| 2026-09-25 | Body weight | 82 | kg | S |
| 2026-09-25 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-09-25 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-25 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-25 | Heart rate | 64 | /min | S |
| 2026-09-25 | Respiratory rate | 14 | /min | S |
| 2026-09-25 | Body temperature | 36.7 | Cel | S |
| 2026-09-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-27 | Body height | 188 | cm | S |
| 2026-07-27 | Body weight | 80.6 | kg | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-07-27 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-07-27 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-07-27 | Heart rate | 86 | /min | S |
| 2026-07-27 | Respiratory rate | 16 | /min | S |
| 2026-07-27 | Body temperature | 37.6 | Cel | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-23 | Body height | 188 | cm | S |
| 2026-10-23 | Body weight | 82 | kg | S |
| 2026-10-23 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-10-23 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-10-23 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-23 | Heart rate | 62 | /min | S |
| 2026-10-23 | Respiratory rate | 14 | /min | S |
| 2026-10-23 | Body temperature | 36.6 | Cel | S |
| 2026-10-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-27 | Primary care visit for breathlessness, orthopnea, and leg swelling | finished | S |
| 2026-04-10 | Two-week heart failure medication safety check and echocardiogram | finished | S |
| 2026-06-26 | Three-month heart failure and blood pressure review | finished | S |
| 2026-09-25 | Six-month heart failure review with repeat echocardiogram | finished | S |
| 2026-07-27 | Same-day sick visit for vomiting and diarrhea | finished | S |
| 2026-10-23 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Start guideline-directed therapy for HFrEF: sacubitril/valsartan, carvedilol, and empagliflozin, with furosemide for congestion; add spironolactone after the two-week potassium check | completed | GL-HF-2022 | S |
| Check a basic metabolic panel one to two weeks after each renin-angiotensin or mineralocorticoid antagonist change, then every three to six months when stable | completed | GL-CMID-2026, GL-HF-2022 | S |
| Treat to a blood pressure below 130/80 with home blood pressure and daily weight logs; low-sodium diet | completed | GL-HTN-2025, GL-CMID-2026 | S |
| Give intravenous ferric carboxymaltose for iron deficiency with ferritin below 100 ng/mL and transferrin saturation below 20% | completed | GL-HF-2022 | S |
| Tobacco cessation counseling with nicotine replacement and a quit date | completed | GL-TOBACCO-2021 | S |
| Cardiology referral to confirm the diagnosis, review the echocardiogram, and guide titration | completed | GL-HF-2022 | S |
| Repeat echocardiogram three to six months after reaching tolerated doses to decide on device therapy | completed | GL-HF-2022, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Lower blood pressure below 130/80 by the six-month review | 2026-09-25 | completed | Blood pressure 122/76 | S |
| Improve the KCCQ-12 overall summary score by at least 20 points by the three-month review | 2026-06-26 | completed | KCCQ-12 rose from 38 to 64 | S |
| Stop smoking by the three-month review | 2026-06-26 | completed | No cigarettes since April; nicotine patch course completed | S |
| Reach the highest tolerated doses of guideline-directed therapy by the six-month review | 2026-09-25 | completed | Sacubitril/valsartan 49/51 mg twice daily, carvedilol 12.5 mg twice daily, spironolactone, and empagliflozin | S |